Ovarian cancer - paclitaxel (review) (TA55)
Specific, concise statements that act as markers of high-quality, cost-effective patient care
This guidance has been partially updated by ‘Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer (review) (NICE technology appraisal guidance 91).
Recommendations 1.3, 1.4 and 1.5 of TA55 on re-challenge therapy and the second-line treatment of advanced ovarian cancer have been replaced. The recommendations for first-line treatment still stand.
For further information regarding this, please see the 'Review update on the use of paclitaxel (1st line only) in the treatment of ovarian cancer' document under 'Background information'.
- TA55 Ovarian cancer - paclitaxel (review): guidance (Web format)
- Summary: Guidance on the use of paclitaxel in the treatment of ovarian cancer
- Review Decision - October 2009
- Review Proposal - August 2009
- Decision of the Appeal Panel: Appraisal of Paclitaxel for Ovarian Cancer
- Assessment Report: An update of a rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of ovarian cancer
- 2003/004 Following planned review NICE issues updated guidance on paclitaxel for ovarian cancer
- Review update on the use of paclitaxel (1st line only) in the treatment of ovarian cancer
- Media Briefing: Technology appraisal guidance on paclitaxel for ovarian cancer
- Press statement: Review of NICE Technology Appraisal Guidance No.s 28, 45 and 55 - Topotecan, PLDH and paclitaxel for ovarian cancer
This page was last updated: 08 May 2013
Information for the public
Implementation tools and resources
- None available
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.